Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
Total Valuation
Werewolf Therapeutics has a market cap or net worth of $55.33M. The enterprise value is $8.58M.
Market Cap$55.33M
Enterprise Value$8.58M
Share Statistics
Werewolf Therapeutics has 45,729,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,729,000
Owned by Insiders50.22%
Owned by Institutions0.04%
Financial Efficiency
Werewolf Therapeutics’s return on equity (ROE) is -0.96 and return on invested capital (ROIC) is -64.95%.
Return on Equity (ROE)-0.96
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-64.95%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee40.98K
Profits Per Employee-1.53M
Employee Count46
Asset Turnover0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Werewolf Therapeutics is ―. Werewolf Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio34.02
PB Ratio0.87
Price to Fair Value0.87
Price to FCF-1.14
Price to Operating Cash Flow-0.90
PEG Ratio-0.02
Income Statement
In the last 12 months, Werewolf Therapeutics had revenue of 1.89M and earned -70.52M in profits. Earnings per share was -1.63.
Revenue1.89M
Gross Profit71.00K
Operating Income-73.59M
Pretax Income-70.52M
Net Income-70.52M
EBITDA-64.05M
Earnings Per Share (EPS)-1.63
Cash Flow
In the last 12 months, operating cash flow was -63.52M and capital expenditures -123.00K, giving a free cash flow of -63.64M billion.
Operating Cash Flow-63.52M
Free Cash Flow-63.64M
Free Cash Flow per Share-1.39
Dividends & Yields
Werewolf Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.83
52-Week Price Change-50.00%
50-Day Moving Average1.60
200-Day Moving Average1.28
Relative Strength Index (RSI)29.08
Average Volume (3m)1.22M
Important Dates
Werewolf Therapeutics upcoming earnings date is Mar 19, 2026, Before Open (Confirmed).
Last Earnings DateNov 4, 2025
Next Earnings DateMar 19, 2026
Ex-Dividend Date―
Financial Position
Werewolf Therapeutics as a current ratio of 7.45, with Debt / Equity ratio of 24.22%
Current Ratio7.45
Quick Ratio7.45
Debt to Market Cap0.41
Net Debt to EBITDA1.15
Interest Coverage Ratio-15.81
Taxes
In the past 12 months, Werewolf Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Werewolf Therapeutics EV to EBITDA ratio is 0.15, with an EV/FCF ratio of 0.17.
EV to Sales-5.19
EV to EBITDA0.15
EV to Free Cash Flow0.17
EV to Operating Cash Flow0.17
Balance Sheet
Werewolf Therapeutics has $66.61M in cash and marketable securities with $9.64M in debt, giving a net cash position of $56.97M billion.
Cash & Marketable Securities$66.61M
Total Debt$9.64M
Net Cash$56.97M
Net Cash Per Share$1.25
Tangible Book Value Per Share$1.69
Margins
Gross margin is 0.00%, with operating margin of -3904.19%, and net profit margin of -3740.85%.
Gross Margin0.00%
Operating Margin-3904.19%
Pretax Margin-3740.85%
Net Profit Margin-3740.85%
EBITDA Margin-3397.61%
EBIT Margin-3493.85%
Analyst Forecast
The average price target for Werewolf Therapeutics is $7.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.75
Price Target Upside545.83% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast-8.30%